Photopharmics said the first 100 patients have been enrolled in a Phase 3 trial testing its light-based therapy device, Celeste, to treat Parkinson’s disease. The Light for PD trial, which is expected to enroll 300 patients, is evaluating the device’s safety and efficacy at easing both motor and…
A new cell model of Parkinson’s disease is better able than others at capturing the complexity of the toxic protein clumps that characterize the disorder and to do so with useful speed, a study reports. “This technology will pave the way for rapidly developing ‘personalized stem cell models’ from…
The U.S. Food and Drug Administration (FDA) has approved Medtronic’s Asleep Deep Brain Stimulation (DBS) surgery for people with Parkinson’s disease or essential tremor. “This is a significant advancement in our surgical offering, providing another safe and effective option for patients considering DBS,” Amaza Reitmeier, a vice…
The U.S. Food and Drug Administration (FDA) has agreed on the design of the upcoming Phase 2 SUNRISE-PD clinical trial to test BioVie’s oral candidate bezisterim as a first-line, stand-alone treatment for newly diagnosed Parkinson’s disease patients. Upon a protocol review, the agency recommended including assessments of motor…
The Parkinson’s Foundation has awarded more than $1 million in 92 community-based grants across 40 states in the U.S. to improve the quality of life of people with Parkinson’s disease. This year’s funding, which ranges between $10,000 to $25,000 per organization, was awarded to programs that address local Parkinson’s…
A protein called STAT3 protected nerve cells from degeneration and improved behavioral and motor outcomes in a rat model of Parkinson’s disease, a study reveals. STAT3 potentially offers “a new avenue for treatment against Parkinson’s,” researchers wrote in the study “STAT3 protects dopaminergic neurons against…
A study reports that the proteins NAP1 and SINTBAD play a role in regulating mitophagy, a process wherein damaged mitochondria are removed from cells, which is essential for helping them stay healthy. Mitophagy is impaired in Parkinson’s disease. “Targeting these proteins in [nerve cells] could be a potential avenue…
Note: This article was updated Aug. 9, 2024, to correct that the improvement seen in good on time in additional analyses was 1.5 hours per dose. The U.S. Food and Drug Administration (FDA) has approved IPX203, a novel extended-release formulation of levodopa and carbidopa, for Parkinson’s disease.
A new visual diagnostic technique called Cap-QuIC has the potential to advance the early detection of neurodegenerative diseases, such as Parkinson’s disease. “The simplicity and efficiency of Cap-QuIC could lower the barriers to routine screening for neurodegenerative diseases, ultimately leading to earlier intervention and better patient outcomes,” Hye Yoon…
Researchers have developed a new mouse model that affects nerve cells in the eye that could help in studying disease mechanisms and treatment approaches in Parkinson’s disease. The mice are lacking the protein VPS35 in specific cells of the eye and developed protein deposits that contain alpha-synuclein, neurodegeneration, and…
Get regular updates to your inbox.
